Keyphrases
Non-small Cell Lung Cancer (NSCLC)
62%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
56%
Carboplatin
38%
Paclitaxel
35%
Cisplatin
23%
Chemotherapy
23%
Docetaxel
22%
Phase II Study
19%
Lung Cancer
19%
Carboplatin-paclitaxel
13%
Phase I Study
12%
Phase II Trial
12%
Overall Survival
10%
Pemetrexed
9%
Pharmacokinetic Study
9%
Gemcitabine
9%
Pharmacokinetics
9%
Median Survival
9%
Metastatic Non-small Cell Lung Cancer
8%
Radiotherapy
8%
Response Rate
8%
Radiation Therapy
8%
Taxanes
7%
Vinorelbine
7%
Bevacizumab
7%
Non-small Cell Lung Cancer Patients
7%
Eastern Cooperative Oncology Group
7%
Etoposide
7%
Weekly Paclitaxel
6%
Maintenance Therapy
6%
Randomized Trial
6%
Erlotinib
6%
Partial Response
6%
Randomized Phase II Trial
6%
Confidence Interval
6%
Quality of Life
5%
Lung Cancer Patients
5%
Non-squamous Non-small Cell Lung Cancer
5%
Progression-free Survival
5%
Dose-limiting Toxicity
5%
Combined Modality Therapy
5%
Veliparib
5%
Elderly Patients
5%
Maximum Tolerated Dose
5%
Performance Status
5%
Placebo
5%
Chemotherapy Regimen
5%
Nausea
5%
Small Cell Lung Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Paclitaxel
40%
Carboplatin
38%
Chemotherapy
36%
Docetaxel
23%
Cisplatin
22%
Lung Cancer
22%
Malignant Neoplasm
22%
Neoplasm
14%
Overall Survival
13%
Diseases
12%
Small Cell Lung Cancer
11%
Epidermal Growth Factor Receptor
11%
Pemetrexed
10%
Disease
9%
Gemcitabine
9%
Pharmacodynamics
8%
Progression Free Survival
8%
Solid Malignant Neoplasm
8%
Vinorelbine
7%
Bevacizumab
7%
Phase II Trials
7%
Chemoradiation Therapy
7%
Etoposide
6%
Clinical Trial
6%
Biological Marker
6%
Pharmacokinetics
6%
Erlotinib
6%
Adverse Event
5%
Placebo
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
57%
Lung Cancer
24%
Paclitaxel
11%
Overall Survival
10%
Radiation Therapy
10%
Malignant Neoplasm
9%
Carboplatin
9%
Pemetrexed
8%
Oncology
8%
Neoplasm
8%
Maintenance Therapy
8%
Arm
7%
Diseases
7%
Lung
6%
Small Cell Lung Cancer
6%
Clinical Trial
6%
Cisplatin
5%
Progression Free Survival
5%
Hazard Ratio
5%
Epidermal Growth Factor Receptor
5%
Bevacizumab
5%
Non-Small Cell Lung Cancer
5%